HealthLeaders Media September 23, 2022
Robin Robinson

The massive infusion puts Verily in a good deal-making position as the health-tech arena grows.

KEY TAKEAWAYS

– The infusion will support Verily’s initiatives in data platforms and research and technology that individualize healthcare.

– Analysts have compared Verily’s funding to Amazon’s acquisition of One Medical – both strategies increase their footprints in the healthcare technology market.

– Verily CEO Andy Conrad will become executive chairman of the Verily Board and current president Stephen Gillett will advance to CEO, effective January 2023.

Verily Life Sciences plans to use its newest $1 billion investment round, led by its parent company, Alphabet, to support expanding its focus on precision health, which includes initiatives in real world evidence generation, healthcare data platforms, and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Bruker brokers $392M deal for frayed NanoString
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
23andMine: CEO Wojcicki aims to take genetics company private
AI That Predicts Targeted Cancer Drug Response with Single-Cell Precision

Share This Article